Lombard Medical, Inc. announced today the pricing of the initial public
offering of 5,000,000 ordinary shares at a price to the public of $11
per share. The shares will be listed on the NASDAQ Global Market under
the ticker symbol "EVAR" on April 25, 2014. In addition, Lombard
Medical, Inc. has granted the underwriters a 30-day option to purchase
up to an additional 750,000 ordinary shares from Lombard Medical, Inc.
In advance of Lombard Medical, Inc.'s shares commencing trading on the
NASDAQ Global Market, trading in the shares of Lombard Medical
Technologies PLC on the AIM market of the London Stock Exchange will be
suspended and trading in the shares will be cancelled.
Jefferies LLC and Barclays Capital Inc. are acting as joint book-running
managers for the proposed offering, and BTIG, LLC is acting as
A registration statement relating to these securities has ben filed
with, and declared effective by, the Securities and Exchange Commission.
The offering will be made only by means of a prospectus, copies of which
may be obtained from Jefferies LLC, Equity Syndicate Prospectus
Department, by email at Prospectus_Department@Jefferies.com,
by phone at 877-547-6340 or by mail at 520 Madison Avenue, 2nd Floor,
New York, NY 10022 or Barclays Capital Inc., c/o Broadridge Financial
Solutions, by email at Barclaysprospectus@broadridge.com,
by phone at 888-603-5847 or by mail at 1155 Long Island Avenue,
Edgewood, NY 11717.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Lombard Medical, Inc.
Lombard Medical, Inc. will become the parent company of Lombard Medical
Technologies PLC ("LMT"), a medical device company focused on device
solutions for the $1.4 billion per annum abdominal aortic aneurysm
repair market following a court approved scheme of arrangement. LMT's
lead product, Aorfix™, is an endovascular stent graft which has been
specifically designed to solve the problems that exist in treating
complex tortuous anatomy, which is often present in advanced AAA
disease. LMT is headquartered in Oxfordshire, England with US operations
in Irvine, CA. Lombard Medical, Inc. is registered in the Cayman Islands.
[ Back To NFVZone's Homepage ]